glp 1 agonist muscle loss Revolutionary weight-loss drugs like Wegovy come with a catch GLP1 Receptor Agonists—Effects beyond Obesity
Description
67 PEG-loxenatide, Chinas first long-acting GLP-RA product, was approved for marketing in China in May 2019
doi:10.1038/nrcardio.2017.224 46
49 In another phase 1 study conducted in 37 Japanese patients, the most common treatment-related side effects were nausea, vomiting, abdominal discomfort, diarrhea, and headache, mostly mild to moderate in severity
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
